Analysis of the Clinical Efficacy of Recombinant Human Vascular Endo-thelial Inhibitor Injection Combined with Chemotherapy in the Treatment of Intermediate and Advanced Non-small Cell Lung Cancer
Objective To analyze the clinical efficacy of recombinant human vascular endothelial inhibitor injection combined with chemotherapy in the treatment of intermediate and advanced non-small cell lung cancer.Methods A total of 80 patients with advanced non-small cell lung cancer treated in Binzhou Central Hospital from January 2019 to January 2023 were randomly selected as the study objects,and randomly divided into control group(n=40,chemo-therapy alone)and study group(n=40,recombinant human endostatin injection combined with chemotherapy)accord-ing to random nember table method.Compared the recent clinical efficacy,serum squamous cell carcinoma antigen(SCC),carcinoembryonic antigen(CEA),cytokeratin 19 fragments(CYFRA21-1)levels,symptom score improvement,and incidence of adverse reactions between two groups of patients before and after treatment.Results The objective re-mission rate(20.0%)and disease control rate(85.0%)of the study group were significantly higher than those of the control group(5.0%and 65.0%),and the differences were statistically significant(χ2=4.114,4.267,both P<0.05).Af-ter treatment,the serum levels of SCC,CEA,CYFRA21-1 and symptom score of the study group were better than those of the control group,and the differences were statistically significant(all P<0.05).There was no statistically sig-nificant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Analysis Re-combinant human endostatin injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer has a good effect,and is significantly better than chemotherapy alone.
Recombinant human vascular endothelial inhibitor injectionChemotherapyIntermediate and advanced non-small cell lung cancerClinical efficacy
万方数据
维普
